Revolution In Heart Failure

Restore Medical has developed the first and only transcatheter Pulmonary Artery Banding  (PAB) system for the treatment of HFrEF patients

ContraBand™ is an innovative and reversible therapy for the treatment of left ventricle (LV) failure. The catheter-delivered implant is designed to leverage the right ventricle (RV) to provide support to the LV, improving LV ejection fraction and restoring optimal ventricular geometry. With no approved treatments currently available for this condition, ContraBand™ has the potential to transform the way congestive heart failure (CHF) patients are treated.

Ongoing Clinical trial have demonstrated that ContraBand™ is a highly effective and safe treatment for patients with LV failure. The implantation procedure for ContraBand™ is simple and time effective. 

Value proposition

Fully reversible

Fully reversible

Time effective

Time effective

Restore the favorable left ventricular geometry

Restore the favorable left ventricular geometry

Improve patients’ quality of life

Improve patients’ quality of life

About

Restore Medical is dedicated to improve the treatment of congestive heart failure (CHF) by developing innovative and disruptive medical device that will reduce hospitalizations, mortality, and morbidity.

Management Team

Gilad Marom

CEO
Read More

Stephen Bellomo

CTO and Co-Founder
Read More

Aida Bibliowicz

VP of Clinical Affairs
Read More

Elchanan Brukheimer, MBBS

Co-Founder & CMO
Read More

Eyal Lifschitz

Chairman of the Board of Directors
Read More

SAB

Elazer Edelman, MD

Read More

Sean Pinney, MD

Read More

Shmuel Banai, MD

Read More

Azeem Latib, MD 

Read More

Offer Amir, MD

Read More

Stefan Verheye, MD

Read More

News & Media

Restore Medical Announces Successful First-In-Human Preliminary Results of Its CONTRABAND™ System for Symptomatic Systolic Heart Failure Patients

Restore Medical, a privately held medical device company, has successfully completed enrollment of the First In Human clinical study with its CONTRABAND™ device for Symptomatic Systolic Heart Failure Patients.
See More

Restore Medical secures €2.5 million in EU funding for cardiac implants to treat heart failure

The Israeli company will receive an additional equity investment of €10 million from the European Innovation Council subject to a future milestone
See More

Restore Medical Announces First in Human Trial for Treatment of Heart Failure in Patients

ContraBand™ technology helps restore the heart’s functionality and may significantly improve patients’ quality of life
See More

Contact

Call: (972) 76-5303888

Email: info@restoremedical.co

Address: 6 Yoni Netanyahu St., Floor 1
Or Yehuda 6037604, Israel

Find us on Linkedin

This project has received funding from the European Union’s Horizon Europe under grant agreement. No. 190178748

Restore Medical Ltd. 2023 © All Rights Reserved

●

face 2 face – Web Development

Gilad Marom

CEO

As CEO of Restore Medical, Gilad Marom brings more than 20 years of experience in medical device development to the company. Prior to joining Restore Medical, Gilad held executive positions at Edwards Lifesciences in both Israel and Irvine, USA, where he successfully oversaw the development of three cardiovascular implants from inception to clinical success.

Stephen Bellomo

CTO and Co-Founder

Stephen brings over 20 years of experience in medical device development to Restore Medical. He has held leadership positions as Vice President of R&D, Vice President of Clinical Affairs, and Chief Technology Officer in several medical device and biotech companies.

Aida Bibliowicz

VP of Clinical Affairs

Aida  brings over 20 years of experience in clinical development to her role as Vice President of Clinical Affairs at Restore Medical. Prior to joining the company, Aida served as VP Clinical Affairs at several companies where she successfully led the development of new drug treatments, achieving marketing approval in the US. With her expertise in clinical development and regulatory affairs, Aida plays a critical role in ensuring that Restore Medical’s technologies are clinically safe and effective, and meet regulatory requirements.

Elchanan Brukheimer, MBBS

Co-Founder & CMO

Dr. Bruckheimer is the Director of the Cardiac Catheterization Laboratories at Schneider Children’s Medical Center, Israel. He received his medical degree from the University of London, specialized in General Pediatrics at the Shaarei Zedek Medical Center, Jerusalem and later specialized in Pediatric Interventional Cardiology at Yale University, USA. Dr. Bruckheimer is a leading expert on 3D imaging and interventional cardiology for the treatment of congenital and structural heart disease and serves regularly on faculty at leading international meetings including TCT (Transcatheter Cardiovascular Therapeutics), PICS-AICS, CSI, ICI and the Veith symposium.

Eyal Lifschitz

Chairman of the Board of Directors

Eyal Lifschitz is Co-founder & Managing General Partner at Peregrine Ventures, a global life science venture capital fund dedicated to improving patients’ quality of life by investing in and supporting life-changing healthcare opportunities.

Eyal is an entrepreneur and investor with years of experience in establishing and managing life science companies and their business development efforts

Elazer Edelman, MD

Elazer Edelman, MD, PhD is the Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital. Prof. Edelman directs MIT’s Institute for Medical Engineering and Science (IMES) and Clinical Research Center (CRC) as well as the Harvard-MIT Biomedical Engineering Center (BMEC). Prof. Edelman holds an MD from Harvard Medical School, PhD in Medical Engineering and Medical Physics from MIT, MS degree in Electrical Engineering and Computer Sciences from MIT, and BS in Bioelectrical Engineering and in Applied Biology from MIT.

Sean Pinney, MD

Sean Pinney is Professor of Medicine, Philip J. and Harriet L. Goodhart Chief of Cardiology and Associate Director of Cardiovascular Clinical Institute at Mount Sinai Morningside. Dr. Pinney is an active clinical researcher who has led both NIH and industry-sponsored trials in the areas of heart failure, cardiac transplantation and mechanical circulatory support. He serves on the editorial boards of JACC, JACC Heart Failure, the Journal of Heart & Lung Transplantation and the Journal of Cardiac Failure. He serves on the AST Board of Directors, is a member of the Georgetown Medical Alumni Board and is past President of the New York Cardiothoracic Transplant Consortium.

Shmuel Banai, MD

Prof. Banai is the Director of the Division of Cardiology and the Head of Interventional Cardiology at the Tel Aviv Medical Center, Tel Aviv, Israel. He is a full academic Professor of Cardiology at the Tel Aviv University, Sackler School of Medicine. Head, of the Nicholas and Elizabeth Slezak Super Center for Cardiac Research and Biomedical Engineering, and the Walton Chair of Interventional Cardiology at the Tel Aviv University. Prof. Banai is the author of more than 200 peer-reviewed papers and book chapters and has participated in many clinical and pre-clinical research studies in the field of cardiology, interventional cardiology, and pharmacotherapy.

Azeem Latib, MD

Dr. Latib is the Section Head and Director of Interventional Cardiology as well as the Director of Structural Heart Interventions at the Montefiore-Einstein Center for Heart and Vascular Care. He is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3). He has over 550 peer-reviewed journal articles to his name. He serves on the editorial board of many journals, including Cardiac Interventions Today, the Journal of the American College of Cardiology, Cardiovascular Interventions and Cardiovascular Revascularization Medicine. Dr Latib is a member of several professional organisations, including the American College of Cardiology and the European Society of Cardiology.

Offer Amir, MD

Prof. Offer Amir, MD, FACC, FESC is the Director of the Heart Institute, Hadassah Medical Center in Jerusalem and a Professor of Cardiovascular Medicine at the Hadassah-Hebrew University. Prof. Amir is a board member of the Heart Failure Association of the ESC (HFA) and was the president of the Israel Heart Society.

Stefan Verheye, MD

Dr. Stefan Verheye, MD, PhD, is a senior interventional cardiologist at the Antwerp Cardiovascular Center, Antwerp Belgium. He is a member of the European Association of Percutaneous Cardiovascular Interventions, a member of the Belgian Working Group on Interventional Cardiology, and has been appointed as Clinical Professor Interventional Cardiology at the University of Brussels. Dr. Verheye is the author of over 150 peer-reviewed journals, ten book chapters, over 400 abstracts, and has led (as global principal investigator) and participated in numerous clinical (Phase I and II) and pre-clinical research studies in the field of innovative interventional cardiology (coronary artery disease, structural heart disease.

Skip to content